Agile Therapeutics Company Profile (NASDAQ:AGRX)

About Agile Therapeutics

Agile Therapeutics logoAgile Therapeutics, Inc. is a women's health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company's lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGRX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.24
  • 50 Day Moving Average: $2.40
  • 200 Day Moving Average: $5.90
  • 52-Week Range: $1.82 - $8.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.85
  • P/E Growth: 0.00
  • Market Cap: $64.42M
  • Outstanding Shares: 28,757,000
  • Beta: 2.02
Profitability:
  • Return on Equity: -57.50%
  • Return on Assets: -40.30%
Debt:
  • Debt-to-Equity Ratio: 0.26%
  • Current Ratio: 6.55%
  • Quick Ratio: 6.55%
Additional Links:
Companies Related to Agile Therapeutics:

Analyst Ratings

Consensus Ratings for Agile Therapeutics (NASDAQ:AGRX) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (391.07% upside)

Analysts' Ratings History for Agile Therapeutics (NASDAQ:AGRX)
Show:
DateFirmActionRatingPrice TargetDetails
1/27/2017RBC Capital MarketsSet Price TargetBuy$8.00View Rating Details
1/4/2017Cantor FitzgeraldSet Price TargetBuy$7.00View Rating Details
1/4/2017FBR & CoSet Price TargetBuy$10.00View Rating Details
1/5/2017Janney Montgomery ScottReiterated RatingBuy$15.00View Rating Details
8/9/2016Noble FinancialReiterated RatingBuy$15.00View Rating Details
2/2/2016Royal Bank of CanadaReiterated RatingOutperform$13.00 -> $15.00View Rating Details
11/10/2015William BlairReiterated RatingBuy$18.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Agile Therapeutics (NASDAQ:AGRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
11/7/2016Q3($0.35)($0.27)ViewN/AView Earnings Details
5/9/2016Q1($0.38)($0.27)ViewN/AView Earnings Details
8/13/2015($0.37)($0.38)ViewN/AView Earnings Details
5/12/2015($0.35)($0.35)ViewN/AView Earnings Details
3/26/2015($0.40)($0.37)ViewN/AView Earnings Details
11/13/2014($0.50)($0.34)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agile Therapeutics (NASDAQ:AGRX)
Current Year EPS Consensus Estimate: $-1.15 EPS
Next Year EPS Consensus Estimate: $-1.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.46)($0.30)($0.38)
Q2 20162($0.29)($0.27)($0.28)
Q3 20162($0.34)($0.32)($0.33)
Q4 20162($0.30)($0.28)($0.29)
Q1 20171($0.28)($0.28)($0.28)
Q2 20171($0.27)($0.27)($0.27)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.52)($0.52)($0.52)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agile Therapeutics (NASDAQ:AGRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Agile Therapeutics (NASDAQ:AGRX)
Insider Ownership Percentage: 3.50%
Institutional Ownership Percentage: 83.55%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/27/2016Jay MoorinMajor ShareholderBuy393,700$6.35$2,499,995.00View SEC Filing  
6/2/2015Alfred AltomariCEOBuy2,500$8.73$21,825.00View SEC Filing  
1/23/2015Jay MoorinMajor ShareholderBuy811,966$5.85$4,750,001.10View SEC Filing  
5/29/2014Care Capital Iii LlcMajor ShareholderBuy500,000$6.00$3,000,000.00View SEC Filing  
5/23/2014Andrew N SchiffDirectorBuy1,333,333$6.00$7,999,998.00View SEC Filing  
5/22/2014Ab InvestorMajor ShareholderBuy1,000,000$6.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Agile Therapeutics (NASDAQ:AGRX)
DateHeadline
News IconAgile Therapeutics, Inc. NASDAQ:AGRX Sees High Volatility in Session - Aiken Advocate (NASDAQ:AGRX)
aikenadvocate.com - February 23 at 8:25 PM
News IconAnalysts Peer Into Their Crystal Balls For Agile Therapeutics, Inc. (NASDAQ:AGRX): Where Is It headed? - Winfield Review (NASDAQ:AGRX)
winfieldreview.com - February 23 at 3:25 PM
us.rd.yahoo.com logoAGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Agile Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:AGRX)
us.rd.yahoo.com - February 23 at 1:26 AM
prnewswire.com logoAGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class ... - PR Newswire (press release) (NASDAQ:AGRX)
www.prnewswire.com - February 22 at 8:25 PM
finance.yahoo.com logoAGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class ... - Yahoo Finance (NASDAQ:AGRX)
finance.yahoo.com - February 22 at 3:24 PM
4-traders.com logoAgile Therapeutics Inc : Lawsuit for Investors in NASDAQ: AGRX Shares against Agile Therapeutics Inc. Announced by Shareholders Foundation (NASDAQ:AGRX)
www.4-traders.com - February 22 at 11:38 AM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline - March 7, 2017 (NASDAQ:AGRX)
finance.yahoo.com - February 22 at 11:38 AM
finance.yahoo.com logoLawsuit for Investors in NASDAQ: AGRX Shares against Agile Therapeutics Inc. Announced by Shareholders Foundation (NASDAQ:AGRX)
finance.yahoo.com - February 21 at 3:41 PM
finance.yahoo.com logoIMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:AGRX)
finance.yahoo.com - February 21 at 3:41 PM
News IconBrokerage Expectations in Spotlight for Agile Therapeutics, Inc. (NASDAQ:AGRX) - Rockville Register (NASDAQ:AGRX)
rockvilleregister.com - February 21 at 6:34 AM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:AGRX)
finance.yahoo.com - February 19 at 6:35 AM
News IconWhat are Research Firms Saying About Agile Therapeutics, Inc. (NASDAQ:AGRX)? - Aiken Advocate (NASDAQ:AGRX)
aikenadvocate.com - February 18 at 3:22 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of Commencement … (NASDAQ:AGRX)
finance.yahoo.com - February 18 at 9:31 AM
us.rd.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 7, 2017 – AGRX (NASDAQ:AGRX)
us.rd.yahoo.com - February 18 at 9:31 AM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AGRX (NASDAQ:AGRX)
us.rd.yahoo.com - February 18 at 9:31 AM
businesswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of Commencement of a ... - Business Wire (press release) (NASDAQ:AGRX)
www.businesswire.com - February 17 at 6:42 PM
us.rd.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:AGRX)
us.rd.yahoo.com - February 16 at 8:29 PM
us.rd.yahoo.com logoAGRX NOTICE: Rosen Law Firm Reminds Agile Therapeutics Investors of Important Class Action Deadline – AGRX (NASDAQ:AGRX)
us.rd.yahoo.com - February 16 at 8:29 PM
News IconShare Inspection for Agile Therapeutics Inc (AGRX) - Baxter Review (NASDAQ:AGRX)
baxternewsreview.com - February 16 at 3:28 PM
News IconIs The Sell-Side Predicting That Agile Therapeutics, Inc. (NASDAQ:AGRX) Will Move Higher? - Winfield Review (NASDAQ:AGRX)
winfieldreview.com - February 16 at 3:28 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile ... - Yahoo Finance (NASDAQ:AGRX)
finance.yahoo.com - February 16 at 7:24 AM
globenewswire.com logoAgile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:AGRX)
globenewswire.com - February 16 at 7:24 AM
News IconAre Analysts Optimistic About Where Agile Therapeutics, Inc. (NASDAQ:AGRX) is Heading? - Winfield Review (NASDAQ:AGRX)
winfieldreview.com - February 16 at 7:24 AM
globenewswire.com logoAGRX NOTICE: Rosen Law Firm Reminds Agile Therapeutics Investors of Important Class Action Deadline – AGRX - GlobeNewswire (press release) (NASDAQ:AGRX)
globenewswire.com - February 16 at 7:24 AM
finance.yahoo.com logoAgile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference (NASDAQ:AGRX)
finance.yahoo.com - February 14 at 8:41 PM
seekingalpha.com logoAgile Therapeutics (AGRX) Presents at 19th Annual BIO CEO & Investor Conference (NASDAQ:AGRX)
seekingalpha.com - February 14 at 3:40 PM
us.rd.yahoo.com logoAGRX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:AGRX)
us.rd.yahoo.com - February 14 at 1:20 AM
businesswire.com logoAGRX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile ... - Business Wire (press release) (NASDAQ:AGRX)
www.businesswire.com - February 13 at 8:18 PM
finance.yahoo.com logoAGRX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile ... - Yahoo Finance (NASDAQ:AGRX)
finance.yahoo.com - February 13 at 3:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 … (NASDAQ:AGRX)
finance.yahoo.com - February 11 at 8:25 PM
us.rd.yahoo.com logoMarch 7 Deadline Alert: Law Offices of Howard G. Smith Reminds Agile Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm (NASDAQ:AGRX)
us.rd.yahoo.com - February 11 at 8:25 PM
us.rd.yahoo.com logoSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In Agile Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline (NASDAQ:AGRX)
us.rd.yahoo.com - February 11 at 8:25 PM
News IconMarket Scout: Checking the Levels for Agile Therapeutics Inc (AGRX) - Davidson Register (NASDAQ:AGRX)
davidsonregister.com - February 10 at 3:51 PM
News IconReviewing Indicator Levels for Agile Therapeutics Inc (AGRX) - Piedmont Register (NASDAQ:AGRX)
piedmontregister.com - February 9 at 1:33 AM
News IconAGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile ... - EconoTimes (NASDAQ:AGRX)
www.econotimes.com - February 8 at 8:32 PM
globenewswire.com logoAGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong ... - GlobeNewswire (press release) (NASDAQ:AGRX)
globenewswire.com - February 8 at 3:29 PM
finance.yahoo.com logoAGRX SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Agile Therapeutics, Inc. and a Lead Plaintiff Deadline of March 7, 2017 (NASDAQ:AGRX)
finance.yahoo.com - February 8 at 3:29 PM
finance.yahoo.com logoSHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Agile Therapeutics, Inc. (AGRX) and Lead Plaintiff Deadline: March 7, 2017 (NASDAQ:AGRX)
finance.yahoo.com - February 7 at 3:43 PM
finance.yahoo.com logoINVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:AGRX)
finance.yahoo.com - February 7 at 3:43 PM
News IconStock Trickling Lower Heading Into The Open: Agile Therapeutics, Inc. (NASDAQ:AGRX) - Aiken Advocate (NASDAQ:AGRX)
aikenadvocate.com - February 6 at 3:27 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, … (NASDAQ:AGRX)
finance.yahoo.com - February 4 at 8:30 PM
globenewswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of a Class Action ... - GlobeNewswire (press release) (NASDAQ:AGRX)
globenewswire.com - February 4 at 1:34 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:AGRX)
finance.yahoo.com - February 4 at 1:34 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agile Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – AGRX (NASDAQ:AGRX)
finance.yahoo.com - February 3 at 8:31 PM
News IconSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of a Class Action ... - EconoTimes (NASDAQ:AGRX)
www.econotimes.com - February 3 at 3:28 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Agile Therapeutics, Inc. (AGRX) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit (NASDAQ:AGRX)
finance.yahoo.com - February 3 at 3:28 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Class Action Lawsuit against Agile Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm (NASDAQ:AGRX)
finance.yahoo.com - February 3 at 3:28 PM
feeds.benzinga.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Agile Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 7, 2017 – AGRX (NASDAQ:AGRX)
feeds.benzinga.com - February 3 at 12:49 PM
globenewswire.com logoAgile Therapeutics to Present at the 2017 BIO CEO & Investor ... - GlobeNewswire (press release) (NASDAQ:AGRX)
globenewswire.com - February 3 at 1:27 AM
finance.yahoo.com logoAgile Therapeutics to Present at the 2017 BIO CEO & Investor Conference - Yahoo Finance (NASDAQ:AGRX)
finance.yahoo.com - February 2 at 8:26 PM

Social

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Where is Agile Therapeutics' stock going? Where will Agile Therapeutics' stock price be in 2017?

5 analysts have issued 12-month price objectives for Agile Therapeutics' stock. Their forecasts range from $7.00 to $15.00. On average, they anticipate Agile Therapeutics' stock price to reach $11.00 in the next year.

When will Agile Therapeutics announce their earnings?

Agile Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Agile Therapeutics stock?

Here are some recent quotes from research analysts about Agile Therapeutics stock:

  • Cantor Fitzgerald analysts commented, "Early this morning, AGRX announced the receipt of ~$3M in non-dilutive funding from converting unused Net Operating Loss (NOL) carryovers via the New Jersey Technology Business Tax Certificate Transfer Program. The addition of $3M, in our calculation, keeps their cash value through year- end at ~$50M, which should fund operations through 2017. This is the second time AGRX has used the program, converting ~$6M in Dec." (12/1/2016)

  • According to Zacks Investment Research, "Agile Therapeutics, Inc. is a women's health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The Company's lead product candidate is Twirla (TM), also known as AG200-15, a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Agile Therapeutics, Inc. is headquartered in Princeton, New Jersey. " (5/11/2016)

Who owns Agile Therapeutics stock?

Agile Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ProQuest Associates IV LLC (17.60%), Vivo Capital LLC (5.26%), Franklin Resources Inc. (4.72%), Perceptive Advisors LLC (2.30%), Deerfield Management Co. (1.38%) and Royce & Associates LP (1.12%). Company insiders that own Agile Therapeutics stock include Alfred Altomari and Jay Moorin.

Who sold Agile Therapeutics stock? Who is selling Agile Therapeutics stock?

Agile Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, J. Goldman & Co LP and Franklin Resources Inc..

Who bought Agile Therapeutics stock? Who is buying Agile Therapeutics stock?

Agile Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Deerfield Management Co., Highland Capital Management LP, Renaissance Technologies LLC, First Light Asset Management LLC and State Street Corp. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari and Jay Moorin.

How do I buy Agile Therapeutics stock?

Shares of Agile Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Agile Therapeutics stock cost?

One share of Agile Therapeutics stock can currently be purchased for approximately $2.24.

Agile Therapeutics (NASDAQ:AGRX) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Earnings History Chart

Earnings by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Dividend History Chart

Dividend Payments by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Last Updated on 2/24/2017 by MarketBeat.com Staff